CoChat

Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight

Ji, Linong, Jiang, Hongwei, Bi, Yan, Li, Hua, Tian, Junhang, Liu, Dexue, Zhao, Yuzhu, Qiu, Wei, Huang, Chongbing, Chen, Lei, Zhong, Shao, Han, Jie, Zhang, Yawei, Lian, Qiufang, Yang, Ping, Lv, Lingchun, Gu, Jieyu, Liu, Zihan, Deng, Huan, Wang, Yanqi, Li, Li, Pei, Lijuan, Qian, Lei · 2025 · New England Journal of Medicine

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Evidence suggests that incretin-based dual agonist pharmacotherapy is helpful in persons with obesity. Mazdutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, may have efficacy in persons with overweight or obesity. METHODS: In a phase 3, double-blind, placebo-controlled trial in China, we randomly assigned, in a 1:1:1 ratio, adults 18 to 75 years of age who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 28 or had a BMI of 24 to less than 28 plus at least one weight-related coexisting condition to receive 4 mg of mazdutide, 6 mg of mazdutide, or placebo for 48 weeks. The two primary end points were the percentage change in body weight from baseline and a weight reduction of at least 5% at week 32, as assessed in a treatment-policy estimand analysis (which assessed effects regardless of early discontinuation of mazdutide or placebo and the initiation of new antiobesity therapies). RESULTS: Among 610 participants, the mean body weight was 87.2 kg and the mean BMI was 31.1 at baseline. At week 32, the mean percentage change in body weight from baseline was -10.09% (95% confidence interval [CI], -11.15 to -9.04) in the 4-mg mazdutide group, -12.55% (95% CI, -13.64 to -11.45) in the 6-mg mazdutide group, and 0.45% (95% CI, -0.61 to 1.52) in the placebo group, and 73.9%, 82.0%, and 10.5% of the participants, respectively, had a weight reduction of at least 5% (P<0.001 for all comparisons with placebo). At week 48, the mean percentage change in body weight from baseline was -11.00% (95% CI, -12.27 to -9.73) in the 4-mg mazdutide group, -14.01% (95% CI, -15.36 to -12.66) in the 6-mg mazdutide group, and 0.30% (95% CI, -0.98 to 1.58) in the placebo group, and 35.7%, 49.5%, and 2.0% of the participants, respectively, had a weight reduction of at least 15% (P<0.001 for all comparisons with placebo). Beneficial effects on all prespecified cardiometabolic measures were seen with mazdutide. The most frequently reported adverse events were gastrointestinal and mostly mild to moderate in severity. The incidence of adverse events leading to discontinuation of the trial regimen was 1.5% with the 4-mg mazdutide dose, 0.5% with the 6-mg mazdutide dose, and 1.0% with placebo. CONCLUSIONS: In Chinese adults with overweight or obesity, once-weekly mazdutide at a dose of 4 mg or 6 mg for 32 weeks led to clinically relevant reductions in body weight. (Funded by Innovent Biologics; GLORY-1 ClinicalTrials.gov number, NCT05607680.).

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa2411528

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Cited by

See all 125

Metadata

Authors
Ji, L., Jiang, H., Bi, Y., Li, H., Tian, J., Liu, D., Zhao, Y., Qiu, W., Huang, C., Chen, L., Zhong, S., Han, J., Zhang, Y., Lian, Q., Yang, P., Lv, L., Gu, J., Liu, Z., Deng, H., Wang, Y., Li, L., Pei, L., & Qian, L.
Affiliations
  • Peking University People's Hospital (CN)
  • Henan University of Science and Technology (CN)
  • Nanjing Drum Tower Hospital (CN)
  • Central Hospital of Zibo (CN)
  • Department of Endocrinology, Luoyang Third People’s Hospital, Luoyang, China
  • Nanyang Medical College (CN)
  • Shenyang Fifth People Hospital (CN)
  • Huzhou Central Hospital (CN)
  • Department of Endocrinology, People’s Hospital of Xuancheng, Xuancheng, China
  • Suzhou Municipal Hospital (CN)
  • First People's Hospital of Kunshan (CN)
  • China National Petroleum Corporation (China) (CN)
  • Jiangxi Pingxiang People's Hospital (CN)
  • Yan'an University (CN)
  • Jilin University (CN)
  • Lishui Central Hospital (CN)
  • Innovent Biologics (China) (CN)
Venue
New England Journal of Medicine
Published
2025-06-12
Volume
392
Issue
22
Pages
2215-2225
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4410717436
Cited by
125
References
32
Citations by year
2026: 86 · 2025: 39
FWCI
70.16
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
Innovent Biologics
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
obesity, overweight, weight loss, GLP-1 receptor agonists, glucagon receptor agonist, weekly dosing, body mass index, weight-related comorbidities, treatment policy estimand, Chinese adults, dose comparison, early discontinuation
MeSH terms
East Asian People, Glucagon-Like Peptide-1 Receptor Agonists, Adolescent, Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Obesity, Peptides, Weight Loss, Body Mass Index, Treatment Outcome, Receptors, Glucagon, Anti-Obesity Agents, Overweight, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. https://app.cochat.ai/papers/10.1056/nejmoa2411528
The paper
Ji, L., Jiang, H., Bi, Y., Li, H., Tian, J., Liu, D., Zhao, Y., Qiu, W., Huang, C., Chen, L., Zhong, S., Han, J., Zhang, Y., Lian, Q., Yang, P., Lv, L., Gu, J., Liu, Z., Deng, H., . . . Qian, L. (2025). Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2411528

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.